Agomelatine, an innovative pharmacological response to unmet needs

  title={Agomelatine, an innovative pharmacological response to unmet needs},
  author={Yann Le Strat and Philip Gorwood},
  journal={Journal of Psychopharmacology},
  pages={4 - 8}
Abstract Most of the available antidepressants, with different pharmacological profiles, such as inhibitors of serotonin reuptake (SSRIs) or norepinephrine reuptake (NRIs) or both (SNRIs), have limitations leading some patients to drop out of treatment. Another direction of research has therefore been undertaken, based initially on the fact that affective disorders are most often characterized by abnormal patterns of circadian rhythms. This consideration has led to the synthesis of agomelatine… 

Agomelatine: The Novel Antidepressant

Considering favorable results on the efficacy and safety of agomelatine in treating depression, it could be a good, safe treatment alternative in the treatment of depression.

The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.

The role of the melatonergic system in MDD is summarized, some data suggest that agomelatine has not only antidepressant effects but also anxiolytic effects, with a potential benefit both on anxiety symptoms associated with MDD and in the treatment of generalised anxiety disorder.

The melatonergic system: effects on sleep and implications for the treatment of psychiatric disorders

The purpose of the present review was to elucidate the effects of the melatonergic system on sleep and the implications for the treatment of psychiatric disorders.

Comparison of the mechanisms of action of antidepressants and their side effects

Comparisons of the mode of action of a drug from a given group of antidepressants and description of its side effects are compared.

Delirium: a disturbance of circadian integrity?

Agomelatine in the treatment of mood and anxiety disorders.

The antidepressant agomelatine combines a novel mechanism of action with certain advantages over currently available antidepressants, in terms of restoration of sleep, absence of treatment-emergent

Pharmacological Treatments for Disordered Gambling: A Meta-analysis

Results showed that opioid antagonists and mood stabilizers, particularly the glutamatergic agent topiramate combined with a cognitive intervention and lithium for gamblers with bipolar disorders demonstrated promising results, however, more rigorously designed, large-scale randomized controlled trials with extended placebo lead-in periods are necessary.


The primary pharmacokinetic parameters of Agomelatine 25 mg tablets were within the 80 to 125% interval required for bioequivalence as stipulated in the current regulations of the USFDA acceptance criteria.

The effect of melaxen and valdoxan on the activity of the glutathione antioxidant system in rats with experimental hyperthyroidism

Results of this study indicate that melaxen and valdoxan exhibit positive effect on free radical homeostasis and appears to be accompanied by a decrease in the load of the glutathione antioxidant system in comparison with the examined pathology.



Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system

The antidepressant properties of agomelatine are based on its melatonergic actions and 5-HT2c receptor antagonism, both of which are reported for various established antidepressant compounds.

Antidepressant action of agomelatine (S 20098) in a transgenic mouse model

Effect of Agomelatine in the Chronic Mild Stress Model of Depression in the Rat

Its morning activity, which was not inhibited by a melatonin antagonist, indicates that these receptors are certainly required, but not sufficient to sustain the agomelatine efficacy, and it is suggested that the antidepressant-like activity of agomalatine depends on some combination of its melatonin agonist and 5-HT2C antagonist properties.

Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model

The results confirm the antidepressant-like activity of agomelatine and suggest a role of melatonin receptors in its mechanism of action.

Addressing circadian rhythm disturbances in depressed patients

Agomelatine is the first melatonergic antidepressant; an agonist of melatonin MT1 and MT2 receptors, with additional antagonist properties at the 5-HT2C receptors, that combines antidepressant efficacy including quality and efficiency of sleep, with a more favourable side-effect profile than current antidepressant treatments.

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

In contrast to melatonin, and reflecting blockade of 5-HT2C receptors, agomelatine is active in several models of anxiolytic properties in rodents and differs from that of benzodiazepines from which it may also be distinguished by its contrasting influence on corticolimbic monoaminergic pathways.

Major depressive disorder, sleep EEG and agomelatine: an open-label study.

In conclusion agomelatine improved sleep continuity and quality and normalized the distribution of SWS sleep and delta power throughout the night.

Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety

Results indicate the involvement of both the melatonin and the 5-HT2C receptors in the mechanism of anxiolytic-like action of agomelatine.

Depression: a new animal model sensitive to antidepressant treatments

Results presented below indicate that immobility is reduced by different treatments known to be therapeutic in depression including three drugs, iprindole, mianserin and viloxazine which although clinically active show little or no ‘antidepressant’ activity in the usual animal tests.